

Ilan Ben-Zvi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6779007/publications.pdf>

Version: 2024-02-01

75
papers

1,915
citations

393982

19
h-index

276539

41
g-index

78
all docs

78
docs citations

78
times ranked

3061
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydroxychloroquine: From Malaria to Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 145-153.	2.9	465
2	Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. <i>Nature Reviews Rheumatology</i> , 2011, 7, 105-112.	3.5	181
3	Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 854-862.	2.9	147
4	The Impact of Vitamin D on Dendritic Cell Function in Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2010, 5, e9193.	1.1	138
5	Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 704-709.	0.5	70
6	Familial Mediterranean fever without MEFV mutations: a case-control study. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 34.	1.2	51
7	The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF). <i>Gene</i> , 2012, 491, 260-263.	1.0	42
8	Familial Mediterranean fever (FMF) phenotype in patients homozygous to the MEFV M694V mutation. <i>European Journal of Medical Genetics</i> , 2019, 62, 103532.	0.7	39
9	DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 2824.	2.2	32
10	Exertional Leg Pain in Familial Mediterranean Fever: A Manifestation of an Underlying Enthesopathy and a Marker of More Severe Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 3221-3226.	2.9	31
11	Anti-DNA antibodies cross-react with C1q. <i>Journal of Autoimmunity</i> , 2013, 44, 34-39.	3.0	27
12	Familial Mediterranean Fever (FMF) with Proteinuria: Clinical Features, Histology, Predictors, and Prognosis in a Cohort of 25 Patients. <i>Journal of Rheumatology</i> , 2013, 40, 2083-2087.	1.0	27
13	Familial Mediterranean Fever and Incidence of Cancer. <i>Arthritis and Rheumatology</i> , 2018, 70, 127-133.	2.9	27
14	Automated processing of thermal imaging to detect COVID-19. <i>Scientific Reports</i> , 2021, 11, 17489.	1.6	25
15	Baseline clinical predictors of an ultimate giant cell arteritis diagnosis in patients referred to temporal artery biopsy. <i>Clinical Rheumatology</i> , 2016, 35, 1817-1822.	1.0	24
16	Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 3.	1.2	23
17	Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: A pilot study. <i>American Journal of Hematology</i> , 2014, 89, 882-888.	2.0	23
18	Type 2 myocardial infarction in general medical wards. <i>Medicine (United States)</i> , 2019, 98, e17404.	0.4	23

#	ARTICLE	IF	CITATIONS
19	Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study. <i>Respiratory Medicine</i> , 2008, 102, 978-983.	1.3	22
20	Analysis of microRNAs in familial Mediterranean fever. <i>PLoS ONE</i> , 2018, 13, e0197829.	1.1	22
21	Environmental shedding of toxigenic <i>Clostridioides difficile</i> by asymptomatic carriers: A prospective observational study. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1052-1057.	2.8	20
22	Effects of Diabetes Mellitus, Chronic Renal Failure and Hemodialysis on Serum and Salivary Antioxidant Status. <i>Nephron Clinical Practice</i> , 2007, 105, c114-c120.	2.3	19
23	Normal QT dispersion in colchicine-resistant familial Mediterranean fever (FMF). <i>Clinical Rheumatology</i> , 2012, 31, 1093-1096.	1.0	18
24	T helper 17 polarization in familial Mediterranean fever. <i>Genes and Immunity</i> , 2013, 14, 212-216.	2.2	18
25	â€Silentâ€™ carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient. <i>Clinical Genetics</i> , 2012, 82, 288-291.	1.0	17
26	Serum Uric Acid Is Associated With Coronary Artery Calcification. <i>Journal of Clinical Hypertension</i> , 2014, 16, 424-428.	1.0	17
27	Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of <i>Helicobacter pylori</i> : a series of six patients. <i>Rheumatology International</i> , 2018, 38, 141-147.	1.5	17
28	Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review. <i>Rheumatology International</i> , 2020, 40, 663-669.	1.5	17
29	Cardiovascular and Metabolic Risk Factors in Inherited Autoinflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2123-E2128.	1.8	16
30	Association between specimen length and diagnostic yield of temporal artery biopsy. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 222-225.	0.6	16
31	Negative temporal artery biopsy: predictive factors for giant cell arteritis diagnosis and alternate diagnoses of patients without arteritis. <i>Clinical Rheumatology</i> , 2018, 37, 2819-2824.	1.0	16
32	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1334-1342.	0.8	16
33	First Detection of Human Infection With <i>Rickettsia felis</i> in Israel. <i>American Journal of the Medical Sciences</i> , 2010, 340, 343-344.	0.4	14
34	QT dispersion in amyloidosis due to familial Mediterranean fever. <i>Rheumatology International</i> , 2012, 32, 1945-1948.	1.5	14
35	Left Ventricular Hypertrophy Predicts Cardiovascular Events in Hypertensive Patients With Coronary Artery Calcifications. <i>American Journal of Hypertension</i> , 2018, 31, 313-320.	1.0	14
36	Clinical significance of positive anti-â€neutrophil cytoplasmic antibodies without evidence of anti-â€neutrophil cytoplasmic antibodies-associated vasculitis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 940-945.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Salivary \hat{I}^{22} -Microglobulin Analysis in Chronic Kidney Disease and Hemodialyzed Patients. <i>Blood Purification</i> , 2007, 25, 505-509.	0.9	12
38	Exertional leg pain as a manifestation of occult spondyloarthropathy in familial Mediterranean fever: an MRI evaluation. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 482-486.	0.6	12
39	Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine. <i>Rheumatology International</i> , 2019, 39, 517-523.	1.5	11
40	The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome. <i>Clinical Rheumatology</i> , 2016, 35, 233-237.	1.0	10
41	Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2018, 192, 7-17.	1.1	10
42	Toll-like receptor 2 is overexpressed in Familial Mediterranean fever patients and is inhibited by colchicine treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 651-661.	1.4	10
43	P-wave dispersion in systemic AA amyloidosis of familial Mediterranean fever. <i>Clinical Rheumatology</i> , 2011, 30, 1295-1298.	1.0	9
44	Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever. <i>Rheumatology</i> , 2021, 60, 3235-3242.	0.9	9
45	Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever. <i>Israel Medical Association Journal</i> , 2012, 14, 221-4.	0.1	9
46	Inflammation and cardiovascular disease in familial Mediterranean fever. An analysis of hospital admissions for acute cardiovascular event. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 80-85.	0.4	9
47	A Case of Murine Typhus Associated With Large Vessel Infarct of the Spleen. <i>American Journal of the Medical Sciences</i> , 2008, 335, 502-503.	0.4	8
48	Effect of tumor necrosis factor- \hat{I}^{\pm} inhibitors on ambulatory 24-h blood pressure. <i>Blood Pressure</i> , 2017, 26, 24-29.	0.7	8
49	Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature. <i>Rheumatology International</i> , 2018, 38, 1743-1749.	1.5	8
50	IFN \hat{I}^3 potentiates TNF \hat{I}^{\pm} /TNFR1 signaling to induce FAT10 expression in macrophages. <i>Molecular Immunology</i> , 2020, 117, 101-109.	1.0	8
51	Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102339.	0.9	8
52	The prevalence and clinical effect of immunogenicity of TNF- \hat{I}^{\pm} blockers in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 228-232.	0.4	8
53	Exertional muscle pain in familial Mediterranean fever patients evaluated by MRI and 31P magnetic resonance spectroscopy. <i>Clinical Radiology</i> , 2013, 68, 371-375.	0.5	6
54	Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever. <i>Rheumatology</i> , 2022, 61, S1129-S1135.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Physiological Effects of Wearing N95 Respirator on Medical Staff During Prolong Work Hours in Covid-19 Departments. <i>Journal of Occupational and Environmental Medicine</i> , 2022, 64, e378-e380.	0.9	6
56	E148Q MEFV mutation carriage and longevity in individuals of Ashkenazi origin. <i>Immunologic Research</i> , 2013, 56, 371-375.	1.3	5
57	Gender disparities in the functional significance of anemia among apparently healthy adults. <i>European Journal of Haematology</i> , 2017, 98, 435-442.	1.1	5
58	Sex and Gender Differences in Autoimmune Diseases. , 2012, , 101-124.		5
59	Risk factors for severe cranial ischaemic events in patients with giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 88-93.	0.4	5
60	Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases. <i>Joint Bone Spine</i> , 2021, 88, 105201.	0.8	4
61	Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 75-79.	0.4	4
62	Factors associated with suitability of empiric antibiotic therapy in hospitalized patients with bloodstream infections. <i>Journal of Chemotherapy</i> , 2017, 29, 159-163.	0.7	3
63	Normal arterial stiffness in familial Mediterranean fever. Evidence for a possible cardiovascular protective role of colchicine. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 32-37.	0.4	3
64	Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 763-772.	0.7	2
65	Clinical and prognostic significance of elevated ferritin levels in hospitalised adults. <i>Postgraduate Medical Journal</i> , 2022, 98, 622-625.	0.9	2
66	Adult Still's Disease Triggered by Influenza Vaccine. <i>Israel Medical Association Journal</i> , 2021, 23, 196-197.	0.1	2
67	The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3956.	1.8	2
68	Carriage of Mediterranean Fever (MEFV) Mutations in Patients with Postpericardiotomy Syndrome (PPS). <i>Israel Medical Association Journal</i> , 2017, 19, 562-565.	0.1	1
69	Cytokine expression in temporal arteries: comparative analysis between patients with biopsy-positive giant cell arteritis, biopsy-negative giant cell arteritis and biopsy-negative without arteritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 122-129.	0.4	1
70	Environment, Immune Dysfunction, and Systemic Lupus Erythematosus. <i>Molecular and Integrative Toxicology</i> , 2012, , 193-213.	0.5	0
71	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1914-1914.	2.9	0
72	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 1167-1168.	2.9	0

#	ARTICLE	IF	CITATIONS
73	The Israeli Annual FMF, Amyloidosis and Other Autoinflammatory Diseases Meeting (July 2011): a bridge spanning these entities. Israel Medical Association Journal, 2012, 14, 219-20.	0.1	0
74	Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 75-79.	0.4	0
75	CHA2DS2-VASC Score Predicts the Risk of Stroke in Patients Hospitalized to the Internal Medicine Department Without Known Atrial Fibrillation. Journal of General Internal Medicine, 2022, 37, 3355-3360.	1.3	0